Aaron Schimmer (University of Toronto)
Catherine Chen (NCATS)
John McKew (NCATS)
Noel Southall (NCATS)
Wei Zheng (NCATS)
This technology includes the combination therapy of tyrosine kinase inhibitors (TKIs) and tigecycline as a potential new treatment for acute myeloid leukemia (AML). The existing treatments available for AML are not adequate; for patients older than 60, the prognosis is poor, with a two-year survival probability of less than 10%. Tigecycline is a glycylcycline antibiotic that induces cell death via inhibition of mitochondrial protein synthesis. Research in cell lines shows that the following group of TKIs exhibited the synergistic effect with tigecycline for killing AML cells: Erlotinib (EGFR inhibitor), Bosutinib (BCR-Abl, MOR inhibitor), Dasatinib (BCR-Abl, Src inhibitor), Sunitinib (Multiple RTK inhibitor) and Vandetinib (EGFR, VEGFR inhibitor).
The combination therapy of TKI and tigecycline is a potential new treatment for AML.
Current treatment approaches to AML are severely lacking and novel therapeutic strategies are essential.